

Ciro Celsa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5106307/publications.pdf>

Version: 2024-02-01

46
papers

874
citations

430442

18
h-index

500791

28
g-index

47
all docs

47
docs citations

47
times ranked

1647
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273. | 1.8 | 138 |
| 2 | Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3. | 2.4 | 102 |
| 3 | Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Cut</i> , 2022, 71, 593-604. | 6.1 | 62 |
| 4 | Diagnostic performance of endoscopic ultrasound through the needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis. <i>Digestive Endoscopy</i> , 2020, 32, 1018-1030. | 1.3 | 49 |
| 5 | Dynamic angiotensin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 662-673. | 2.5 | 42 |
| 6 | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121. | 1.7 | 41 |
| 7 | The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5613. | 1.8 | 39 |
| 8 | Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: a systematic review and meta-analysis. <i>Endoscopy</i> , 2021, 53, 1037-1047. | 1.0 | 39 |
| 9 | Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1061-1072.e8. | 2.4 | 32 |
| 10 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449. | 1.1 | 29 |
| 11 | First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84. | 4.2 | 29 |
| 12 | Biliary complications after liver transplantation: current perspectives and future strategies. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 76-92. | 0.7 | 27 |
| 13 | Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. <i>PLoS ONE</i> , 2021, 16, e0245281. | 1.1 | 25 |
| 14 | Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAteco COVID19 REgistry (SMACORE). <i>Scientific Reports</i> , 2021, 11, 1137. | 1.6 | 22 |
| 15 | Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. <i>Future Oncology</i> , 2019, 15, 3411-3422. | 1.1 | 21 |
| 16 | Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334. | 1.2 | 21 |
| 17 | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90. | 1.7 | 21 |
| 18 | Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018, 38, 2108-2116. | 1.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132. | 1.7 | 18 |
| 20 | Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958. | 0.4 | 13 |
| 21 | Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. <i>Liver International</i> , 2021, 41, 1105-1116. | 1.9 | 10 |
| 22 | Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897. | 1.7 | 9 |
| 23 | Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. <i>Annals of Hepatology</i> , 2021, , 100568. | 0.6 | 8 |
| 24 | Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019. | 0.4 | 7 |
| 25 | Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study. <i>Endoscopic Ultrasound</i> , 2021, 10, 440. | 0.6 | 7 |
| 26 | Consequences of Extended Spectrum Beta-lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients. <i>Liver Transplantation</i> , 2021, 27, 43-54. | 1.3 | 5 |
| 27 | Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592. | 1.7 | 5 |
| 28 | Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507. | 1.3 | 5 |
| 29 | Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. <i>Diagnostics</i> , 2022, 12, 1308. | 1.3 | 4 |
| 30 | Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2179-2188. | 1.9 | 3 |
| 31 | The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938. | 0.9 | 3 |
| 32 | Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> , 0, , . | 0.2 | 3 |
| 33 | Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221. | 0.4 | 3 |
| 34 | Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. <i>Gastroenterology Insights</i> , 2022, 13, 117-126. | 0.7 | 3 |
| 35 | Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1048-1053. | 0.5 | 2 |
| 36 | Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 237-238. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Editorial: proton pump inhibitor use in cirrhosisâ€”a piece of the puzzle. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 663-664. | 1.9 | 2 |
| 38 | Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114. | | 1 |
| 39 | Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?. <i>Recenti Progressi in Medicina</i> , 2018, 109, 605-608. | 0.8 | 1 |
| 40 | Systemic therapies for hepatocellular carcinoma: the present and the future. <i>Recenti Progressi in Medicina</i> , 2021, 112, 110-116. | 0.8 | 1 |
| 41 | Validation and refinement of PROSASH model using the neutrophilâ€”lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020, 1, 6-11. | 0.2 | 0 |
| 42 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449. | | 0 |
| 43 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449. | | 0 |
| 44 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449. | | 0 |
| 45 | The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449. | | 0 |
| 46 | Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022, 12, 1187. | 1.3 | 0 |